New immunotherapy cocktail aims to outsmart biliary cancer
NCT ID NCT07654530
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a combination of two immunotherapy drugs (sintilimab and ipilimumab) plus chemotherapy (albumin-bound paclitaxel and gemcitabine) as a first treatment for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery. The study aims to see if this new mix can shrink tumors better than current standard treatments. About 107 participants will receive the drug combination, and researchers will track how many respond and how long they live without the cancer growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sintilimab, ipilimumab, albumin-bound paclitaxel, and gemcitabine
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment for advanced biliary tract cancer, potentially improving response rates and survival beyond current chemoimmunotherapy.
- What could go wrong
- This is an early-phase (Phase 2) trial with only 107 participants, so results may not be definitive. The drug combination may cause significant side effects, and the benefit over existing therapies is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCERS (BTC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.